Articles

Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation

Oliver Langselius , Harriet Rumgay, Esther de Vries, David C Whiteman et al. Int J Cancer. 2025 Sep 15;157(6):1110-1119

Cutaneous melanoma (CM) accounted for around 331,700 cancer cases globally in 2022. Ultraviolet radiation (UVR) is a major CM risk factor. In this study, we update and improve global estimates of UVR-attributable CM cases. An estimated 267,353 CM cases were UVR attributable globally in 2022. Males contributed to a larg... Read More

15 Apr, 2026

Global in cutaneous malignant melanoma incidence and mortality

Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, et al. Melanoma Res. 2024 Jun 1;34(3):265-275

Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in many high-income countries. However, incidence has been increasing in several countries. Mortality from CMM in all age groups showed a favorable pattern in the majority of the countries consid... Read More

15 Apr, 2026

Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review

Xia Wei, Samuel Oxley, Ranjit Manchanda et al. Cancers 2022, 14, 6117

This systematic review found that surgical prevention is cost-effective for women in high-income countries who are at a high risk of breast cancer, intermediate/high risk of ovarian cancer and high risk of endometrial cancer. Synthesized cost-effectiveness evidence is necessary for resource allocation for risk-reducing... Read More

15 Apr, 2026

The importance of genetics for timing and extent of surgery in inherited colorectal cancer syndromes

Rami James N Aoun and Matthew F Kalady. Surg Oncol. 2022 Aug: 43:101765

Approximately 5% of colorectal cancers arise within an inherited colorectal cancer syndrome, with known underlying genetic etiologies. These syndromes increase the risk of colorectal and extracolonic cancers. Identification of a specific genetic pathogenic variant defines the syndrome, and quantifies the elevated risks... Read More

15 Apr, 2026

A systematic review of economic burden of colorectal cancer

Abdosaleh Jafari, Fatemeh A Hosseini, Faride S Jalali et al.Health Sci Rep. 2024 Aug 21;7(8):e70002

Colorectal cancer is the third most common cancer in the Western Hemisphere. It is the third most common cancer in men after prostate and lung cancers and the second most common cancer in women after breast cancer. The data from 37 studies dealing with the costs of patients with colorectal cancer were extracted. Most o... Read More

15 Apr, 2026

Global, regional and national burden of colon and rectum cancer attributable to high fasting plasma glucose: a systematic analysis for the Global Burden of Disease Study 2021

Ke Lu and Gang Xu. Front Oncol 2026 Feb 27:16:1690349

Colorectal cancer (CRC), the third most common malignant cancer globally, imposes a substantial public health burden. Emerging evidence has highlighted hyperglycemia as an independent risk factor for CRC. Globally, high fasting plasma glucose (FPG)-related CRC deaths increased from 31,907 (1990) to 82,421 (2021), with ... Read More

15 Apr, 2026

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death

Michael Bretthauer, Magnus Løberg, Paulina Wieszczy, et al. N Engl J Med. 2022;387:1547-1556

We performed a pragmatic, randomized trial involving presumptively healthy men and women 55 to 64 years of age drawn from population registries in Poland, Norway, Sweden, and the Netherlands between 2009 and 2014. The participants were randomly assigned in a 1:2 ratio either to receive an invitation to undergo a single... Read More

15 Apr, 2026

Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II

Jyh-Ming Liou , Peter Malfertheiner , Tzu-Chan Hong , et al. Gut. 2025 Oct 8;74(11):1767-1791

Eradication of H pylori, the primary cause of gastric cancer, reduces the risk of gastric cancer across all age groups, with the greatest risk reduction before the onset of premalignant conditions. H pylori eradication also promotes ulcer healing, prevents ulcer recurrence and reduces the risk of NSAID/aspirin related ... Read More

15 Apr, 2026

Tyrer-Cuzick Lifetime Risk Is Not Associated With Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma

Divya Rao , Chloe Wernecke, Lisa Baron, et al. Breast J. 2026 Jan 19:2026:8670441

The Tyrer-Cuzick (TC) or IBIS risk calculator is a widely used tool to estimate the probability of developing breast cancer. The TC is commonly used to guide patients toward further diagnostic imaging, genetic testing, chemoprevention, or risk-reducing surgery. A population of 964 patients with TC was evaluated for 12 ... Read More

15 Apr, 2026

Breast cancer genetics and risk assessment: an overview for the clinician

L Larkin. Climacteric. 2023 Jun;26(3):229-234

Breast cancer is the most common cancer in women globally with enormous associated morbidity, mortality and economic impact. Prevention of breast cancer is a global public health imperative. To date, most of our global efforts have been directed at expanding population breast cancer screening programs for early cancer ... Read More

15 Apr, 2026